Posts by Mourabit Halima

On October 18, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Forum grandly opened, gathering significant global advancements in breast cancer. In the era following CDK4/6 inhibitors for hormone receptor-positive (HR+) breast cancer, targeted endocrine therapies based on the PIK3CA/AKT1/PTEN pathway have brought new hope to patients. At this conference, Dr. Virginia Kaklamani from The University of Texas MD Anderson Cancer Center shared important insights on the progress of treating HR+ metastatic breast cancer and discussed post-CDK4/6 inhibitor strategies and clinical practice experiences for HR+ advanced breast cancer in the "Viewpoint · SIBCS Special" column of Oncology Horizon.

Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong Yang from the Breast Surgery Department of Fudan University Shanghai Cancer Center led a session discussing "Implant Complications." Following the event, Oncology Frontier interviewed Dr. Yang to delve into key issues surrounding implant reconstruction.

From September 25 to 29, 2024, the 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held in Xiamen. Themed "Patient-Centered, Shared Future," the conference attracted tens of thousands of oncology experts and pharmaceutical elites from home and abroad to discuss the latest advancements in cancer prevention and treatment, cutting-edge technologies, and future trends. During the conference, Oncology Frontier had the honor of interviewing Dr. Shukui Qin, one of the founders and Vice President of CSCO. In this interview, Professor Qin reflected on CSCO’s remarkable journey since its founding in 1997, including its development through three major phases: preparation, institutionalization, and cultural growth. Supported by the Party and the government, CSCO has actively promoted five core tasks: continuing medical education in clinical oncology, academic exchanges, clinical research, expert consensus formulation, and patient services, achieving remarkable progress. Professor Qin highlighted the extraordinary progress in primary liver cancer treatment, from stagnation to breakthroughs, emphasizing CSCO’s ongoing efforts to foster multidisciplinary collaboration, strengthen basic and translational research, and explore "combination strategies" to significantly improve the survival rates of liver cancer patients.

During the 2024 CACA Integrated Esophageal Cancer Academic Conference, Dr. Shaoming Wang from the Cancer Hospital Chinese Academy of Medical Sciences gave an in-depth explanation of research progress on the burden of upper gastrointestinal cancer. During the conference, Oncology Frontier had the pleasure of interviewing Professor Wang to further explore his team’s latest research findings on the global lifetime risk of gastrointestinal cancer.

From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase important research advancements and trends in the field, both domestically and internationally. For over two decades, CSCO has been at the forefront of clinical oncology development in China, and numerous experts and scholars have played integral roles in its evolution, growing along with CSCO. To honor this journey, Oncology Frontier has established a special column, "Growing Together with CSCO," to reflect on these experiences with Chinese scholars. In this inaugural issue, we are pleased to interview Dr. Zefei Jiang, Vice President and Secretary General of CSCO and a professor at the The Fifth Medical Center of Chinese PLA General Hospital, who shares his personal journey of growth with CSCO and highlights the exciting features of the 2024 CSCO Conference.

As one of the world's largest and most academically prestigious clinical oncology conferences, the 2024 European Society for Medical Oncology (ESMO) conference, held from September 13 to 17 in Barcelona, drew global attention. The conference revealed several important clinical study results in upper gastrointestinal tumors. Dr. Filippo Pietrantonio, an oncologist from the National Cancer Institute in Milan, Italy, shared his insights in an exclusive interview with Oncology Frontier.